GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma
Phase 2
Terminated
- Conditions
- Melanoma
- Interventions
- Biological: GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 5
- Registration Number
- NCT00706238
- Locations
- 🇳🇴
GSK Investigational Site, Oslo, Norway
The Expression of Antigens in Bone Marrow Samples From Volunteering Donors.
Completed
- Conditions
- Cancer
- Interventions
- Procedure: Bone marrow aspiration
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00706199
- Locations
- 🇧🇪
GSK Investigational Site, Ottignies, Belgium
A Study With Darapladib to Collect Tolerability Information
Phase 1
Completed
- Conditions
- Atherosclerosis
- Interventions
- Drug: SB-480848 (darapladib)
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2
- Registration Number
- NCT00704431
- Locations
- 🇺🇸
GSK Investigational Site, King of Prussia, Pennsylvania, United States
A First Time in Human Study of GSK586529 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Depressive Disorder and Anxiety Disorders
- Interventions
- Drug: GSK586529 capsulesDrug: GSK586529 tabletsDrug: Placebo
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 21
- Registration Number
- NCT00703547
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study to Investigate the Effect of Inhaling Single Doses of Different Formulations of GW642444M in Asthmatic Patients
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00702910
- Locations
- 🇳🇿
GSK Investigational Site, Wellington, New Zealand
Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease
Phase 3
Completed
- Conditions
- Herpes Simplex
- Interventions
- Biological: Herpes simplex candidate vaccine- adjuvanted GSK208141Biological: Placebo injection
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2491
- Registration Number
- NCT00699764
An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.
Phase 3
Completed
- Conditions
- Healthy SubjectsSleep Initiation and Maintenance Disorders
- Interventions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 91
- Registration Number
- NCT00699608
- Locations
- 🇬🇧
GSK Investigational Site, Guildford, Surrey, United Kingdom
Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults
Phase 1
Completed
- Conditions
- Herpes Simplex
- Interventions
- Biological: Herpes simplex candidate (gD) vaccine GSK208141
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT00698893
Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Recurrent Small-cell Lung Cancer (SCLC)Lung Cancer, Small Cell
- Interventions
- Drug: Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT00698516
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y
Phase 2
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: HBV-MPL vaccineBiological: Engerix™-B
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2008-06-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 163
- Registration Number
- NCT00698555
- Locations
- 🇧🇪
GSK Clinical Trials Call Center, Gent, Belgium
© Copyright 2025. All Rights Reserved by MedPath